Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.
about
Intravenous Immunoglobulins as a Treatment for Alzheimerʼs DiseaseImmunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease.Biological markers of amyloid beta-related mechanisms in Alzheimer's diseaseAntigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosisAutoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implicationsCurrent status of biomarker research in neurologyNatural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the AgedAnti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid AngiopathyReduced β-amyloid pathology in an APP transgenic mouse model of Alzheimer's disease lacking functional B and T cellsCharacterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology.Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.Dominant inheritance of retinal ganglion cell resistance to optic nerve crush in mice.Immunological memory to hyperphosphorylated tau in asymptomatic individuals.Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study.Can peripheral leukocytes be used as Alzheimer's disease biomarkers?Biomarkers in Alzheimer's disease: past, present and future.Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.Antigen-bound and free β-amyloid autoantibodies in serum of healthy adults.Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's diseaseA human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide.A lipoprotein receptor cluster IV mutant preferentially binds amyloid-β and regulates its clearance from the mouse brainAltered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease.Alzheimer's disease with spastic paresis and cotton wool type plaques.γ-Synuclein antibodies have neuroprotective potential on neuroretinal cells via proteins of the mitochondrial apoptosis pathway.ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjectsAutoreactive-Aβ antibodies promote APP β-secretase processing.Biomarkers of Alzheimer disease in plasmaThe immune system, amyloid-beta peptide, and Alzheimer's disease.Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia.Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease.Mechanisms of action of naturally occurring antibodies against β-amyloid on microglia.Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues.Naturally occurring autoantibodies interfere with β-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer's disease 24 h after single treatment.Antibodies to potato virus Y bind the amyloid beta peptide: immunohistochemical and NMR studiesThe role of microglia in amyloid clearance from the AD brain.Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients.Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease.The role of the immune system in clearance of Abeta from the brain.
P2860
Q22241424-0D583D50-CA88-4156-8009-E7B3D72F0E5FQ24599108-5F5D7B35-DB0E-45DA-AC56-7B0DEEB6D0FDQ24622136-12D6FACB-02F5-4062-81E0-1AE673099C48Q24646892-91008C7D-C582-463B-8494-7DF4293407B6Q26740418-D7C9CFAD-8A27-437D-ABDD-4A47AD22303CQ26744505-AE48F14B-ACF4-4C16-8375-021A588E15CEQ26752508-36A88CDC-64F6-4728-9697-4FC1CCDD178CQ26781451-66776FBA-8418-4246-BB2B-45DC0C734F4EQ27317159-1EB40340-974D-461A-B594-703CA46615CCQ30315907-F7F9EE4D-D824-4763-808E-18ADB3CD217FQ30489052-D5689AE2-1A37-4C93-9175-6F45EFC4B8A7Q33276940-BDD08D72-A3AA-415C-BBBD-4EFAE9FC3091Q33559360-EDD38087-7FE6-47B9-9586-44263C0F3BEAQ33625476-2FBA8806-B2B8-4215-A82B-7BD26E10FB39Q33689076-64EC40E9-C2B0-4C47-A0A8-AF11F55AB6D3Q33791646-03F0A2F4-D0CC-4ABD-BA49-6E5C7C469975Q34098866-F29FDD9A-4D4F-4C0B-BC98-3A4CE0F7D459Q34376103-3A081977-FF71-481E-86FF-73DF7655FB09Q34413715-D7979D9D-34C4-429B-AB72-4FD34089FF30Q34419295-10CF2F76-A33F-4CF9-8048-5E5BF312799CQ34473306-DBC44395-0313-4CEF-B830-39D8641A53ACQ34500145-ACAFEE21-0A4F-4F9C-861C-669DACF3FC3EQ34666433-A5D374B4-A19B-46C2-B09B-4B7800B543EAQ34760606-0CADA94F-7C88-46F3-9461-E38AB9463D70Q34976274-DC0C7FFF-7A0F-42C5-81E2-0B75A876A553Q35111136-EDF4E8A4-20F0-4BA4-9B9F-EFB554D9874FQ35184148-592D8077-F742-45FC-A45C-E957EB08F654Q35753932-136A593F-B81D-4D76-A2A9-785B6AF8350BQ36045288-7EA78A85-4B2F-4F8F-86C6-9DA7BBA79F4BQ36121068-16C4BC7A-EC16-409F-88B1-7E131C5C637BQ36179280-46EC42EE-5AF1-4C88-BB70-6586911C3F77Q36342218-57BEADD9-0C45-4D43-AA01-FD4A5C23D31CQ36689356-35A5C474-5E9B-48A7-94EE-0C91C72437A2Q36700047-695C932B-A2C6-4B07-9701-64533E299AA1Q36764469-0AE026AE-1D52-462A-8330-6A7836756747Q36825498-404ECFE4-B27C-4F52-8138-CBC08447C01EQ36841789-1BA4082B-CE0F-413D-B7EB-C5B71EBF735EQ37024947-EAC3AE8E-D5BA-4559-A24B-9244C06BC98AQ37044228-149866A8-564C-42ED-A913-5649E73604DAQ37118137-E1AAA06D-8C1E-435D-925C-F93C20DD94AA
P2860
Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.
@ast
Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.
@en
Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.
@nl
type
label
Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.
@ast
Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.
@en
Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.
@nl
prefLabel
Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.
@ast
Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.
@en
Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.
@nl
P2093
P356
P1433
P1476
Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.
@en
P2093
Eastwood B
Moeller HJ
P304
P356
10.1212/WNL.57.5.801
P407
P577
2001-09-01T00:00:00Z